论文部分内容阅读
目的探讨培美曲塞联合奥沙利铂治疗晚期胃癌的临床疗效和安全性。方法回顾性分析观察组33例接受培美曲塞联合奥沙利铂方案化疗的晚期胃癌患者,对照组33例接受培美曲塞单纯用药的晚期胃癌患者,化疗2个周期后,评价疗效及安全性。结果观察组患者治疗后总有效率(RR)为30.3%、疾病控制率(DCR)为84.8%,均显著高于对照组(P>0.05);观察组中位无疾病进展时间(m TTP)为(3.1±0.3)个月,显著长于对照组的(1.9±0.4)个月(P>0.05)。观察组患者不良反应为恶心呕吐5例,白细胞减少3例,血小板减少3例,贫血9例,与对照组比较,差异无统计学意义(P>0.05)。结论培美曲赛联合奥沙利铂方案治疗晚期胃癌有效率高,不良反应小,且患者可耐受,可以改善晚期胃癌患者预后和生活质量。
Objective To investigate the clinical efficacy and safety of pemetrexed combined with oxaliplatin in the treatment of advanced gastric cancer. Methods A retrospective analysis of 33 cases of patients with advanced gastric cancer treated with pemetrexed combined with oxaliplatin chemotherapy in the observation group and 33 cases of patients with advanced gastric cancer treated with pemetrexed alone were given two cycles of chemotherapy. safety. Results The total effective rate (RR) and the rate of disease control (DCR) in the observation group were significantly higher than those in the control group (30.3% vs 84.8%, P 0.05). The median progression free time (m TTP) (3.1 ± 0.3) months, significantly longer than the control group (1.9 ± 0.4) months (P> 0.05). Adverse reactions in the observation group were nausea and vomiting in 5 cases, leukopenia in 3 cases, thrombocytopenia in 3 cases and anemia in 9 cases. There was no significant difference between the two groups (P> 0.05). Conclusion pemetrexed combined with oxaliplatin regimen is effective in treating advanced gastric cancer with small adverse reactions and can be tolerated. It can improve the prognosis and quality of life of patients with advanced gastric cancer.